Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

US10640517B2 · kind B2 · utility

Assignee

• Aurigene Discovery Technologies Limited · IN

Inventors

• Venkateshwar Rao Gummadi · Bengaluru, IN
• Susanta Samajdar · Savanuru, IN

Key dates

• Filing date: Aug 3, 2018
• Grant date: May 5, 2020
• Expiry date: Aug 3, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.